The cancer is over, now what?: Understanding risk, changing outcomes

Cancer

Volumn 117, Issue SUPPL. 10, 2011, Pages 2250-2257

  Oeffinger, Kevin C ^a   Tonorezos, Emily S ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

adolescents; cancer; late effects; risk based healthcare; survivor; young adults

Indexed keywords

CISPLATIN; ACETYLSALICYLIC ACID; ANTHRACYCLINE; BLEOMYCIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PREDNISONE; PROCARBAZINE; VINCRISTINE;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; BREAST CANCER; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CANCER SURVIVOR; CANCER THERAPY; CARDIOVASCULAR DISEASE; CORONARY ARTERY DISEASE; FUNCTIONAL DISEASE; HEALTH CARE DELIVERY; HEALTH STATUS; HIGH RISK POPULATION; HUMAN; MORBIDITY; OUTCOME ASSESSMENT; PHYSICAL ACTIVITY; PRIORITY JOURNAL; RADIATION DOSE; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SOLID TUMOR; TESTIS CANCER; ACUTE GRANULOCYTIC LEUKEMIA; BONE TUMOR; CANCER COMBINATION CHEMOTHERAPY; CANCER INVASION; CANCER RESEARCH; CANCER RISK; CANCER STAGING; CONFERENCE PAPER; DISEASE SEVERITY; DISEASE SURVEILLANCE; DOSE RESPONSE; DRUG EFFECT; FOLLOW UP; GRAFT RECIPIENT; HODGKIN DISEASE; LOW DRUG DOSE; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; PRACTICE GUIDELINE; RADIATION INJURY; SURVIVAL RATE;

ADOLESCENT; ADULT; CHILD; HUMANS; MORBIDITY; NEOPLASMS; NEOPLASMS, SECOND PRIMARY; QUALITY OF LIFE; RISK REDUCTION BEHAVIOR; SURVIVORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79955507916     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26051     Document Type: Review

References (55)

1. Bleyer A, O'Leary M, Barr R, Ries LAG, eds. Cancer epidemiology in older adolescents and young adults 15 to 29 years of age, including SEER incidence and survival: 1975-2000. NIH Pub. No. 06-5767. Bethesda, MD: National Cancer Institute; 2006.
2. Canadian Cancer Society Steering Committee. Canadian cancer statistics 2009. Toronto: Canadian Cancer Society; 2009.
3. Robison LL, Armstrong GT, Boice JD, et al. The Childhood Cancer Survivor Study: a National Cancer Institute-supported resource for outcome and intervention research. J Clin Oncol. 2009; 27: 2308-2318.
4. Lorenzi M, McMillan AJ, Siegel LS, et al. Educational outcomes among survivors of childhood cancer in British Columbia, Canada: report of the Childhood/Adolescent/Young Adult Cancer Survivors (CAYACS) Program. Cancer. 2009; 115: 2234-2245.
5. Mertens AC, Liu Q, Neglia JP, et al. Cause-specific late mortality among 5-year survivors of childhood cancer: the Childhood Cancer Survivor Study. J Natl Cancer Inst. 2008; 100: 1368-1379.
6. Ries LAG, Smith MA, Gurney JG, Linet M, Tamra T, Young JL, Bunin GR, eds. Cancer incidence and survival among children and adolescents: United States SEER Program 1975-1995. NIH Pub. No. 99-4649. Bethesda, MD: National Cancer Institute; 1999.
7. Oeffinger KC, Mertens AC, Sklar CA, et al. Chronic health conditions in adult survivors of childhood cancer. N Engl J Med. 2006; 355: 1572-1582. (Pubitemid 44547808)
8. Hudson MM, Mertens AC, Yasui Y, et al. Health status of adult long-term survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. JAMA. 2003; 290: 1583-1592. (Pubitemid 37430383)
9. O'Brien MM, Donaldson SS, Balise RR, Whittemore AS, Link MP,. Second malignant neoplasms in survivors of pediatric Hodgkin's lymphoma treated with low-dose radiation and chemotherapy. J Clin Oncol. 2010; 28: 1232-1239.
10. Bhatia S, Yasui Y, Robison LL, et al. High risk of subsequent neoplasms continues with extended follow-up of childhood Hodgkin's disease: report from the Late Effects Study Group. J Clin Oncol. 2003; 21: 4386-4394. (Pubitemid 46621816)
11. Dores GM, Metayer C, Curtis RE, et al. Second malignant neoplasms among long-term survivors of Hodgkin's disease: a population-based evaluation over 25 years. J Clin Oncol. 2002; 20: 3484-3494.
12. Sanna G, Lorizzo K, Rotmensz N, et al. Breast cancer in Hodgkin's disease and non-Hodgkin's lymphoma survivors. Ann Oncol. 2007; 18: 288-292. (Pubitemid 46323095)
13. Henderson TO, Amsterdam A, Bhatia S, et al. Systematic review: surveillance for breast cancer in women treated with chest radiation for childhood, adolescent, or young adult cancer. Ann Intern Med. 2010; 152: 444-455; W144-W154.
14. Oeffinger KC, Ford JS, Moskowitz CS, et al. Breast cancer surveillance practices among women previously treated with chest radiation for a childhood cancer. JAMA. 2009; 301: 404-414.
15. Hodgson DC, Hudson MM, Constine LS,. Pediatric Hodgkin lymphoma: maximizing efficacy and minimizing toxicity. Semin Radiat Oncol. 2007; 17: 230-242. (Pubitemid 46970823)
16. Reinders JG, Heijmen BJ, Olofsen-van Acht MJ, van Putten WL, Levendag PC,. Ischemic heart disease after mantlefield irradiation for Hodgkin's disease in long-term follow-up. Radiother Oncol. 1999; 51: 35-42. (Pubitemid 29244089)
17. Aleman BM, van den Belt-Dusebout AW, De Bruin ML, et al. Late cardiotoxicity after treatment for Hodgkin lymphoma. Blood. 2007; 109: 1878-1886. (Pubitemid 46348183)
18. Swerdlow AJ, Higgins CD, Smith P, et al. Myocardial infarction mortality risk after treatment for Hodgkin disease: a collaborative British cohort study. J Natl Cancer Inst. 2007; 99: 206-214.
19. Mulrooney DA, Yeazel MW, Kawashima T, et al. Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort. BMJ. 2009; 339: b4606.
20. Chen AB, Punglia RS, Kuntz KM, Mauch PM, Ng AK,. Cost effectiveness and screening interval of lipid screening in Hodgkin's lymphoma survivors. J Clin Oncol. 2009; 27: 5383-5389.
21. Heidenreich PA, Schnittger I, Strauss HW, et al. Screening for coronary artery disease after mediastinal irradiation for Hodgkin's disease. J Clin Oncol. 2007; 25: 43-49. (Pubitemid 350003049)
22. Rademaker J, Schoder H, Ariaratnam NS, et al. Coronary artery disease after radiation therapy for Hodgkin's lymphoma: coronary CT angiography findings and calcium scores in nine asymptomatic patients. AJR Am J Roentgenol. 2008; 191: 32-37. (Pubitemid 351955179)
23. Fossa SD, Aass N, Harvei S, Tretli S,. Increased mortality rates in young and middle-aged patients with malignant germ cell tumours. Br J Cancer. 2004; 90: 607-612. (Pubitemid 38297198)
24. van den Belt-Dusebout AW, de Wit R, Gietema JA, et al. Treatment-specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol. 2007; 25: 4370-4378. (Pubitemid 350013842)
25. Huddart RA, Norman A, Shahidi M, et al. Cardiovascular disease as a long-term complication of treatment for testicular cancer. J Clin Oncol. 2003; 21: 1513-1523. (Pubitemid 46594104)
26. Haugnes HS, Aass N, Fossa SD, et al. Predicted cardiovascular mortality and reported cardiovascular morbidity in testicular cancer survivors. J Cancer Surviv. 2008; 2: 128-137.
27. Nuver J, Smit AJ, Wolffenbuttel BH, et al. The metabolic syndrome and disturbances in hormone levels in long-term survivors of disseminated testicular cancer. J Clin Oncol. 2005; 23: 3718-3725.
28. Feldman DR, Bosl GJ, Sheinfeld J, Motzer RJ,. Medical treatment of advanced testicular cancer. JAMA. 2008; 299: 672-684. (Pubitemid 351252727)
29. Gietema JA, de Vries EG, Sleijfer DT,. Increased incidence of cardiovascular risk factors in cured testicular cancer patients. J Clin Oncol. 1992; 10: 1652. (Pubitemid 23057998)
30. Gietema JA, Sleijfer DT, Willemse PH, et al. Long-term follow-up of cardiovascular risk factors in patients given chemotherapy for disseminated nonseminomatous testicular cancer. Ann Intern Med. 1992; 116: 709-715. (Pubitemid 23033113)
31. Sagstuen H, Aass N, Fossa SD, et al. Blood pressure and body mass index in long-term survivors of testicular cancer. J Clin Oncol. 2005; 23: 4980-4990. (Pubitemid 46224004)
32. Marras TK, Chan CK, Lipton JH, Messner HA, Szalai JP, Laupacis A,. Long-term pulmonary function abnormalities and survival after allogeneic marrow transplantation. Bone Marrow Transplant. 2004; 33: 509-517. (Pubitemid 38425782)
33. Uderzo C, Pillon M, Corti P, et al. Impact of cumulative anthracycline dose, preparative regimen and chronic graft-versus-host disease on pulmonary and cardiac function in children 5 years after allogeneic hematopoietic stem cell transplantation: a prospective evaluation on behalf of the EBMT Pediatric Diseases and Late Effects Working Parties. Bone Marrow Transplant. 2007; 39: 667-675. (Pubitemid 46813583)
34. Chemaitilly W, Sklar CA,. Endocrine complications of hematopoietic stem cell transplantation. Endocrinol Metab Clin N Am. 2007; 36: 983-998; ix. (Pubitemid 350026254)
35. Ando M, Ohashi K, Akiyama H, et al. Chronic kidney disease in long-term survivors of myeloablative allogeneic haematopoietic cell transplantation: prevalence and risk factors. Nephrol Dial Transplant. 2010; 25: 278-282.
36. Choi M, Sun CL, Kurian S, et al. Incidence and predictors of delayed chronic kidney disease in long-term survivors of hematopoietic cell transplantation. Cancer. 2008; 113: 1580-1587.
37. Baker KS, Ness KK, Steinberger J, et al. Diabetes, hypertension, and cardiovascular events in survivors of hematopoietic cell transplantation: a report from the bone marrow transplantation survivor study. 2007; 109: 1765-1772.
38. Meacham LR, Sklar CA, Li S, et al. Diabetes mellitus in long-term survivors of childhood cancer. Increased risk associated with radiation therapy: a report for the childhood cancer survivor study. Arch Intern Med. 2009; 169: 1381-1388.
39. Majhail NS, Flowers ME, Ness KK, et al. High prevalence of metabolic syndrome after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2009; 43: 49-54.
40. Majhail NS, Lazarus HM, Burns LJ,. A orospective study of iron-overload management in allogeneic hematopoietic-cell transplant survivors. Biol Blood Marrow Transplant. 2010; 16: 832-837.
41. Majhail NS, DeFor T, Lazarus HM, Burns LJ,. High prevalence of iron overload in adult allogeneic hematopoietic cell transplant survivors. Biol Blood Marrow Transplant. 2008; 14: 790-794. (Pubitemid 351773155)
42. Ness KK, Bhatia S, Baker KS, et al. Performance limitations and participation restrictions among childhood cancer survivors treated with hematopoietic stem cell transplantation: the bone marrow transplant survivor study. Arch Pediatr Adolesc Med. 2005; 159: 706-713. (Pubitemid 41126832)
43. Gurney JG, Ness KK, Rosenthal J, Forman SJ, Bhatia S, Baker KS,. Visual, auditory, sensory, and motor impairments in long-term survivors of hematopoietic stem cell transplantation performed in childhood: results from the Bone Marrow Transplant Survivor study. Cancer. 2006; 106: 1402-1408. (Pubitemid 43363921)
44. Campbell S, Sun CL, Kurian S, et al. Predictors of avascular necrosis of bone in long-term survivors of hematopoietic cell transplantation. Cancer. 2009; 115: 4127-4135.
45. Savani BN, Donohue T, Kozanas E, et al. Increased risk of bone loss without fracture risk in long-term survivors after allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2007; 13: 517-520. (Pubitemid 46585937)
46. Tauchmanova L, Colao A, Lombardi G, Rotoli B, Selleri C,. Bone loss and its management in long-term survivors from allogeneic stem cell transplantation. J Clin Endocrinol Metab. 2007; 92: 4536-4545. (Pubitemid 350223422)
47. Bhatia S, Louie AD, Bhatia R, et al. Solid cancers after bone marrow transplantation. J Clin Oncol. 2001; 19: 464-471. (Pubitemid 32112860)
48. Rizzo JD, Curtis RE, Socie G, et al. Solid cancers after allogeneic hematopoietic cell transplantation. Blood. 2009; 113: 1175-1183.
49. Oeffinger KC,. Longitudinal risk-based health care for adult survivors of childhood cancer. Curr Probl Cancer. 2003; 27: 143-167. (Pubitemid 36627186)
50. Oeffinger KC, Hudson MM, Landier W,. Survivorship: childhood cancer survivors. Primary Care. 2009; 36: 743-780.
51. Children's Oncology Group. Long-term follow-up guidelines for survivors of childhood, adolescent, and young adult cancers. Version 3.0. Arcadia, CA: Children's Oncology Group; 2008.
52. Landier W, Bhatia S, Eshelman DA, et al. Development of risk-based guidelines for pediatric cancer survivors: the Children's Oncology Group long-term follow-up guidelines from the Children's Oncology Group late effects committee and nursing discipline. J Clin Oncol. 2004; 22: 4979-4990. (Pubitemid 46638624)
53. Nathan PC, Greenberg ML, Ness KK, et al. Medical care in long-term survivors of childhood cancer: a report from the childhood cancer survivor study. J Clin Oncol. 2008; 26: 4401-4409.
54. Oeffinger KC, Nathan PC, Kremer LC,. Challenges after curative treatment for childhood cancer and long-term follow-up of survivors. Pediatr Clin North Am. 2008; 55: 251-273. (Pubitemid 351173184)
55. Oeffinger KC, McCabe MS,. Models for delivering survivorship care. J Clin Oncol. 2006; 24: 5117-5124. (Pubitemid 46623197)